Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
. (2018) Theme 7 Pre-clinical therapeutic strategies. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:sup1, pages 217-239.
Read now
Read now
Iyas Daghlas, Teresa E. Lever & Emily Leary. (2018) A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:3-4, pages 206-211.
Read now
Read now
Koji Takei, Kikumi Tsuda, Fumihiro Takahashi, Manabu Hirai & Joseph Palumbo. (2017) An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 88-97.
Read now
Read now
Bello Hamidou, Benoit Marin, Geraldine Lautrette, Marie Nicol, William Camu, Philippe Corcia, Marie-Christine Arnes-Bes, Christine Tranchant, Pierre Clavelou, Didier Hannequin, Giroud Maurice, Katell Beauvais, Jean-Christophe Antoine, Véronique Danel-Brunaud, Fausto Viader, Pierre-Marie Preux & Philippe Couratier. (2017) Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:7-8, pages 519-527.
Read now
Read now
Jeremy M. Shefner, Andrew A. Wolff, Lisa Meng, Amy Bian, Jacqueline Lee, Donna Barragan & Jinsy A. Andrews. (2016) A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 17:5-6, pages 426-435.
Read now
Read now
Emiliano Peña-Altamira, Federica Prati, Francesca Massenzio, Marco Virgili, Antonio Contestabile, Maria Laura Bolognesi & Barbara Monti. (2016) Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation. Expert Opinion on Therapeutic Targets 20:5, pages 627-640.
Read now
Read now
Verena C Haringer & Summer B Gibson. (2015) Amyotrophic lateral sclerosis: clinical perspectives. Orphan Drugs: Research and Reviews 5, pages 19-31.
Read now
Read now
Abigail DeLoach, Michael Cozart, Arianna Kiaei & Mahmoud Kiaei. (2015) A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies. Expert Opinion on Drug Discovery 10:10, pages 1099-1118.
Read now
Read now
Koji Abe, Yasuto Itoyama, Gen Sobue, Shoji Tsuji, Masashi Aoki, Manabu Doyu, Chikuma Hamada, Kazuoki Kondo, Takatomo Yoneoka, Makoto Akimoto & Hiide Yoshino. (2014) Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15:7-8, pages 610-617.
Read now
Read now
Philippe Corcia & Paul H Gordon. (2012) Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Therapeutics and Clinical Risk Management 8, pages 359-366.
Read now
Read now
John A Morren & Nestor Galvez-Jimenez. (2012) Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs 21:3, pages 297-320.
Read now
Read now
. (2011) ALSUntangled No. 8: Low dose naltrexone for ALS. Amyotrophic Lateral Sclerosis 12:1, pages 76-78.
Read now
Read now
Angela Genge, Steven Wainwright & Christine Vande Velde. Amyotrophic lateral sclerosis: exploring pathophysiology in the context of treatment. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 0:0, pages 1-12.
Read now
Read now
Articles from other publishers (59)
Wen Cao & Dongsheng Fan. (2023) Neutrophils: a subgroup of neglected immune cells in ALS. Frontiers in Immunology 14.
Crossref
Crossref
Luca Muzio, Alma Ghirelli, Federica Agosta & Gianvito Martino. 2023. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment
523
537
.
Jeremy M. Shefner, Richard Bedlack, Jinsy A. Andrews, James D. Berry, Robert Bowser, Robert Brown, Jonathan D. Glass, Nicholas J. Maragakis, Timothy M. Miller, Jeffrey D. Rothstein & Merit E. Cudkowicz. (2022) Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers. JAMA Neurology 79:12, pages 1312.
Crossref
Crossref
Giuseppe Schirò, Vincenzo Di Stefano, Salvatore Iacono, Antonino Lupica, Filippo Brighina, Roberto Monastero & Carmela Rita Balistreri. (2022) Advances on Cellular Clonotypic Immunity in Amyotrophic Lateral Sclerosis. Brain Sciences 12:10, pages 1412.
Crossref
Crossref
Arielle Kasindi, Dieu-Trang Fuchs, Yosef Koronyo, Altan Rentsendorj, Keith Black & Maya Koronyo-Hamaoui. (2022) Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation. Cells 11:9, pages 1578.
Crossref
Crossref
Elise Liu, Léa Karpf & Delphine Bohl. (2021) Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons. Frontiers in Molecular Neuroscience 14.
Crossref
Crossref
María Laura Palumbo, Alejandro David Moroni, Sofía Quiroga, María Micaela Castro, Adriana Laura Burgueño & Ana María Genaro. (2021) Immunomodulation induced by central nervous system‐related peptides as a therapeutic strategy for neurodegenerative disorders. Pharmacology Research & Perspectives 9:5.
Crossref
Crossref
Fabiola De Marchi, Ivana Munitic, Amedeo Amedei, James D. Berry, Eva L. Feldman, Eleonora Aronica, Giovanni Nardo, Donatienne Van Weehaeghe, Elena Niccolai, Nikolina Prtenjaca, Stacey A. Sakowski, Caterina Bendotti & Letizia Mazzini. (2021) Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neuroscience & Biobehavioral Reviews 127, pages 958-978.
Crossref
Crossref
Ruojie He, Minying Zheng, Ling Lian & Xiaoli Yao. (2021) Milano–Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis. Cells 10:5, pages 1220.
Crossref
Crossref
Falguni Baidya, Mariya Bohra, Aishika Datta, Deepaneeta Sarmah, Birva Shah, Priya Jagtap, Swapnil Raut, Ankan Sarkar, Upasna Singh, Kiran Kalia, Anupom Borah, Xin Wang, Kunjan R. Dave, Dileep R. Yavagal & Pallab Bhattacharya. (2020) Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. Immunology 162:2, pages 160-178.
Crossref
Crossref
Chunyu Li, Wanchun Yang, Qianqian Wei & Huifang Shang. (2020) Causal Association of Leukocytes Count and Amyotrophic Lateral Sclerosis: a Mendelian Randomization Study. Molecular Neurobiology 57:11, pages 4622-4627.
Crossref
Crossref
Heike J. Wobst, Korrie L. Mack, Dean G. Brown, Nicholas J. Brandon & James Shorter. (2020) The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future. Medicinal Research Reviews 40:4, pages 1352-1384.
Crossref
Crossref
Pamela A. McCombe, John D. Lee, Trent M. Woodruff & Robert D. Henderson. (2020) The Peripheral Immune System and Amyotrophic Lateral Sclerosis. Frontiers in Neurology 11.
Crossref
Crossref
Tereza Filipi, Zuzana Hermanova, Jana Tureckova, Ondrej Vanatko & Miroslava Anderova. (2020) Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. Journal of Clinical Medicine 9:1, pages 261.
Crossref
Crossref
Paulus Stefan Rommer & Johann Sellner. (2019) Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions. Drug Discovery Today 24:7, pages 1398-1404.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2019. The Handbook of Neuroprotection. The Handbook of Neuroprotection
609
641
.
Marlena Wosiski‐Kuhn, Miles S. Lyon, James Caress & Carol Milligan. (2018) Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune‐modulating therapies. Muscle & Nerve 59:1, pages 23-33.
Crossref
Crossref
Sebastiano Giuseppe Crisafulli, Simona Brajkovic, Maria Sara Cipolat Mis, Valeria Parente & Stefania Corti. (2017) Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis. Molecular Neurobiology 55:4, pages 2789-2813.
Crossref
Crossref
Marcelo R. S. Briones, Amanda M. Snyder, Renata C. Ferreira, Elizabeth B. Neely, James R. Connor & James R. Broach. (2018) A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment. Frontiers in Neurology 9.
Crossref
Crossref
Loqman A. Mohamed, Shashirekha Markandaiah, Silvia Bonanno, Piera Pasinelli & Davide Trotti. (2017) Blood–Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. The AAPS Journal 19:6, pages 1600-1614.
Crossref
Crossref
Nakul Katyal & Raghav Govindarajan. (2017) Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement. Frontiers in Neurology 8.
Crossref
Crossref
Syed I. Khalid, Leonel Ampie, Ryan Kelly, Shafeeq S. Ladha & Christopher Dardis. (2017) Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials. Frontiers in Neurology 8.
Crossref
Crossref
Michael P. Gustafson, Nathan P. Staff, Svetlana Bornschlegl, Greg W. Butler, Mary L. Maas, Mohamed Kazamel, Adeel Zubair, Dennis A. Gastineau, Anthony J. Windebank & Allan B. Dietz. (2017) Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLOS ONE 12:7, pages e0182002.
Crossref
Crossref
Roser Masgrau, Carmen Guaza, Richard M. Ransohoff & Elena Galea. (2017) Should We Stop Saying ‘Glia’ and ‘Neuroinflammation’?. Trends in Molecular Medicine 23:6, pages 486-500.
Crossref
Crossref
Dmitry Petrov, Colin Mansfield, Alain Moussy & Olivier Hermine. (2017) ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?. Frontiers in Aging Neuroscience 9.
Crossref
Crossref
N. W. Galwey. (2017) Supplementation of a clinical trial by historical control data: is the prospect of dynamic borrowing an illusion?. Statistics in Medicine 36:6, pages 899-916.
Crossref
Crossref
Christopher A. Shaw. 2017. Neural Dynamics of Neurological Disease. Neural Dynamics of Neurological Disease
301
354
.
Ludo Van Den Bosch. 2017. Disease-Modifying Targets in Neurodegenerative Disorders. Disease-Modifying Targets in Neurodegenerative Disorders
277
296
.
Charles Schutt, Howard E. Gendelman & R. Lee Mosley. 2017. Neuroimmune Pharmacology. Neuroimmune Pharmacology
767
797
.
Michal Schwartz & Aleksandra Deczkowska. (2016) Neurological Disease as a Failure of Brain–Immune Crosstalk: The Multiple Faces of Neuroinflammation. Trends in Immunology 37:10, pages 668-679.
Crossref
Crossref
Jeremy M. ShefnerDawei LiuMelanie L. LeitnerDavid SchoenfeldDonald R. JohnsToby FergusonMerit Cudkowicz. (2016) Quantitative strength testing in ALS clinical trials. Neurology 87:6, pages 617-624.
Crossref
Crossref
Kevin S. Chen, Stacey A. Sakowski & Eva L. Feldman. (2016) Intraspinal stem cell transplantation for amyotrophic lateral sclerosis. Annals of Neurology 79:3, pages 342-353.
Crossref
Crossref
Erik Ellwardt, James T. Walsh, Jonathan Kipnis & Frauke Zipp. (2016) Understanding the Role of T Cells in CNS Homeostasis. Trends in Immunology 37:2, pages 154-165.
Crossref
Crossref
Irene Tramacere, Eleonora Dalla Bella, Adriano Chiò, Gabriele Mora, Graziella Filippini & Giuseppe Lauria. (2015) The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 86:11, pages 1180-1185.
Crossref
Crossref
Renzo Mancuso & Xavier Navarro. (2015) Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Progress in Neurobiology 133, pages 1-26.
Crossref
Crossref
Giuseppe Lauria, Eleonora Dalla Bella, Giovanni Antonini, Giuseppe Borghero, Margherita Capasso, Claudia Caponnetto, Adriano Chiò, Massimo Corbo, Roberto Eleopra, Raffaella Fazio, Massimiliano Filosto, Fabio Giannini, Enrico Granieri, Vincenzo La Bella, Giancarlo Logroscino, Jessica Mandrioli, Letizia Mazzini, Maria Rosaria Monsurrò, Gabriele Mora, Vladimiro Pietrini, Rocco Quatrale, Romana Rizzi, Fabrizio Salvi, Gabriele Siciliano, Gianni Sorarù, Paolo Volanti, Irene Tramacere & Graziella Filippini. (2015) Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. Journal of Neurology, Neurosurgery & Psychiatry 86:8, pages 879-886.
Crossref
Crossref
Benjamin J. Murdock, Diane E. Bender, Benjamin M. Segal & Eva L. Feldman. (2015) The dual roles of immunity in ALS: Injury overrides protection. Neurobiology of Disease 77, pages 1-12.
Crossref
Crossref
Michael Jablonski, David S. Miller, Piera Pasinelli & Davide Trotti. (2015) ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis. Brain Research 1607, pages 1-14.
Crossref
Crossref
Andrea Malaspina, Fabiola Puentes & Sandra Amor. (2015) Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. International Immunology 27:3, pages 117-129.
Crossref
Crossref
Nam-Hee KimMin Oh Lee. (2015) Update of Therapeutic Clinical Trials for Amyotrophic Lateral Sclerosis. Korean Journal of Clinical Neurophysiology 17:1, pages 1.
Crossref
Crossref
Michal Schwartz & Kuti Baruch. (2014) Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: Boosting autoimmunity to fight-off chronic neuroinflammation. Journal of Autoimmunity 54, pages 8-14.
Crossref
Crossref
Hiroshi Mitsumoto, Benjamin R Brooks & Vincenzo Silani. (2014) Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?. The Lancet Neurology 13:11, pages 1127-1138.
Crossref
Crossref
T. Bucky Jones. (2014) Lymphocytes and autoimmunity after spinal cord injury. Experimental Neurology 258, pages 78-90.
Crossref
Crossref
Xiaowei W. Su, James R. Broach, James R. Connor, Glenn S. Gerhard & Zachary Simmons. (2014) Genetic heterogeneity of amyotrophic lateral sclerosis: Implications for clinical practice and research. Muscle & Nerve 49:6, pages 786-803.
Crossref
Crossref
Helmar C. Lehmann, Hubertus Köller & Hans-Peter Hartung. 2014. Textbook of Neural Repair and Rehabilitation. Textbook of Neural Repair and Rehabilitation
655
673
.
. 2014. Textbook of Neural Repair and Rehabilitation. Textbook of Neural Repair and Rehabilitation
509
673
.
John Turnbull. (2014) Why is ALS so Difficult to Treat?. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 41:2, pages 144-155.
Crossref
Crossref
David J. Graber & William F. Hickey. 2014. Neuroinflammation and Neurodegeneration. Neuroinflammation and Neurodegeneration
547
567
.
Merit E Cudkowicz, Leonard H van den Berg, Jeremy M Shefner, Hiroshi Mitsumoto, Jesus S Mora, Albert Ludolph, Orla Hardiman, Michael E Bozik, Evan W Ingersoll, Donald Archibald, Adam L Meyers, Yingwen Dong, Wildon R Farwell & Douglas A Kerr. (2013) Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. The Lancet Neurology 12:11, pages 1059-1067.
Crossref
Crossref
Ravid Shechter & Michal Schwartz. (2012) Harnessing monocyte‐derived macrophages to control central nervous system pathologies: no longer ‘if’ but ‘how’. The Journal of Pathology 229:2, pages 332-346.
Crossref
Crossref
Reto Baldinger, Hans Dieter Katzberg & Markus Weber. (2012) Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Paul H. Gordon & Vincent Meininger. (2011) How can we improve clinical trials in amyotrophic lateral sclerosis?. Nature Reviews Neurology 7:11, pages 650-654.
Crossref
Crossref
A. ChiòA. CanosaS. GalloS. CammarosanoC. MogliaG. FudaA. CalvoM. Gabriele. (2011) ALS clinical trials. Neurology 77:15, pages 1432-1437.
Crossref
Crossref
Amit Bar-Or, Peter Rieckmann, Anthony Traboulsee & V. Wee Yong. (2011) Targeting Progressive Neuroaxonal Injury. CNS Drugs 25:9, pages 783-799.
Crossref
Crossref
Thomas Philips & Wim Robberecht. (2011) Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. The Lancet Neurology 10:3, pages 253-263.
Crossref
Crossref
Shigeko Takeuchi, Noriko Fujiwara, Akemi Ido, Miki Oono, Yuki Takeuchi, Minako Tateno, Keiichiro Suzuki, Ryosuke Takahashi, Ikuo Tooyama, Naoyuki Taniguchi, Jean-Pierre Julien & Makoto Urushitani. (2010) Induction of Protective Immunity by Vaccination With Wild-Type Apo Superoxide Dismutase 1 in Mutant SOD1 Transgenic Mice. Journal of Neuropathology & Experimental Neurology 69:10, pages 1044-1056.
Crossref
Crossref
P.-F. Pradat, S. Attarian, J.-P. Camdessanché, L. Carluer, P. Cintas, P. Corcia, A. Echaniz-Laguna, J. Gonzalez-Bermejo, N. Guy, G. Nicolas, T. Perez, M.-H. Soriani, N. Vandenberghe & A. Verschueren. (2010) La recherche sur la SLA en 2009 : compte rendu du groupe bibliographique de la coordination des centres SLA. Revue Neurologique 166:8-9, pages 683-698.
Crossref
Crossref
Ana G. Barbeito, Pinar Mesci & Séverine Boillée. (2010) Motor neuron–immune interactions: the vicious circle of ALS. Journal of Neural Transmission 117:8, pages 981-1000.
Crossref
Crossref
Michael Benatar, Jerome Kurent & Dan H Moore. (2009) Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews.
Crossref
Crossref